AbbVie (ABBV) Other Operating Expenses (2012 - 2026)

AbbVie (ABBV) has reported Other Operating Expenses for 15 consecutive years, with $5.0 billion the latest figure, recorded in Q1 2026.

• On a quarterly basis, Other Operating Expenses rose 16.75% year-over-year to $5.0 billion in Q1 2026; TTM through Jun 2026 was $5.2 billion, a 20.98% increase from a year earlier, with the FY2025 full-year figure at $241.0 million, up 3342.86% from the prior year.
• Other Operating Expenses was $5.0 billion for Q1 2026 at AbbVie, up from $217.0 million in the prior quarter.
• Over five years, Other Operating Expenses peaked at $5.0 billion in Q1 2026 and troughed at -$229.0 million in Q3 2022.
• A 5-year average of $958.3 million and a median of $96.5 million in 2023 frame the typical range for Other Operating Expenses.
• Across the five-year window, Other Operating Expenses dropped 1.74% in 2023 and soared 3000.0% in 2025, its largest moves.
• Over 5 years, Other Operating Expenses stood at $1.0 million in 2022, then soared by 16800.0% to $169.0 million in 2023, then tumbled by 95.86% to $7.0 million in 2024, then soared by 3000.0% to $217.0 million in 2025, then jumped by 2186.64% to $5.0 billion in 2026.
• The last three Other Operating Expenses figures came in at $5.0 billion (Q1 2026), $217.0 million (Q4 2025), and $24.0 million (Q2 2025), per Business Quant data.